Leishmaniasis is a severe health problem in DCs and Europe. Pentavalent antimonials (SbV)will remain the first line drug for the forthcoming years. Control is being challenged by increased SbV resistance. Our aim is to design molecular tools for detecting emergence and spreading of drug resistance in visceral and mucocutaneous leishmaniases. To achieve this, we will obtain samples from SbV susceptible and refractory patients (Nepal, Bolivia, Peru ), identify molecular modifications associated with SbV resistance in FIELD isolates, transfer this Knowledge into molecular tools for drug resistance diagnosis, and define the population structure of sensitive and resistant isolates for understanding the epidemiological dynamics of drug resistance. Outputs: collection of naturally resistant parasites, knowledge on natural mechanisms generating SbV resistance and its transmission, PCR tools for preventing therapeutic failure and guidelines for their use in epidemiological surveillance.
Funding SchemeCSC - Cost-sharing contracts